The purpose of this legislation, known as the Drug Deal Disclosure Act, is to increase transparency around drug pricing agreements between the federal government and pharmaceutical manufacturers. It aims to ensure that the public has access to information about pricing deals that may affect the cost of medications. Key provisions of the Act require the Department of Health and Human Services (HHS) to publicly release a wide range of documents and communications related to drug pricing agreements within 30 days of the law being enacted.